Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 in BCG-Unresponsive or BCG-Exposed NMIBC
NCT06971614Phase 2Recruiting
- Sponsor
- ImmVira
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of MVR-T3011 in non-muscle-invasive bladder cancer (NMIBC), sponsored by ImmVira. Started Jun 2025; status: recruiting.
02
Drugs
MVR-T3011
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06971614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971614.